Drug: Ipilimumab (Yervoy, Bristol-Myers Squibb)
Status: Approved for pediatric patients 12 years and older with unresectable or metastatic melanoma
Significant Information:
- Ipilimumab was evaluated in 2 trials of pediatric patients: a dose-finding study of 33 patients aged 2 to 21 years with relapsed or refractory or solid tumors and an open-label, single-arm trial in 12 adolescents (aged 12-16 years) with previously treated or untreated, unresectable stage 3 or 4 malignant melanoma
- Overall safety